U.S. FDA Approves VIZIMPRO (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
________________________________ |
|
1 |
World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2018: Lung fact sheet. http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed September 2018 |
2 | Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics. 2009; 3: 215?224. |
3 | Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452?462 |
4 |
American Cancer Society. Detailed Guide: Lung Cancer (Non-Small Cell). Available at: https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed July 2018. |
5 |
Lovly CM, Horn L. Molecular profiling of lung cancer. My Cancer Genome; 2016. Available at:https://www.mycancergenome.org/content/disease/lung-cancer/. Accessed July 2018 |
6 |
Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Onc. 2005; 23:2556-2568. |